business development
Addex' primary goal is to build a cash-generative, profitable and sustainable pharmaceutical business around its core competencies in small molecule discovery and drug development.
Addex believes that it has globally recognized unique expertise in allosteric modulation. Since inception in 2002, the company has recruited some of the leading experts in the field of allosteric modulation from industry and academia.
Addex has established a unique chemical library of over 50,000 allosteric modulators. In addition, the company's scientists have developed highly specialized biological systems for identification and selection of high affinity, orally active small molecule allosteric modulators. Addex is continually running new screenings to find allosteric modulators against targets selected for their clinical and commercial potential.
The allosteric modulator library and unique high-throughput detection systems have enabled Addex to build, in only five years of operation, what it believes to be the largest clinical and preclinical portfolio of proprietary allosteric modulator compounds. Addex believes that its lead compound, ADX10059, is the most advanced mGluR5 allosteric modulator in any clinical trial worldwide.
The pipeline and especially the preclinical portfolio show that Addex' discovery capability is sustainably delivering viable, well differentiated, products. The company's business development strategy, stems from this strength.
